Redcare Pharmacy lifts 2026 revenue outlook again on German Rx strength

• Redcare Pharmacy raised its 2026 total revenue growth forecast to 16%–18%, from 15%–17%.
• German Rx revenue is now forecast at €730–760 million, up from €680–720 million, representing 45%–51% growth.
• The upgrade follows strong German Rx momentum: preliminary figures show year-on-year growth of 56% in Q3 and 51% in September.
• Non-Rx revenue growth guidance remains unchanged at 10%–12%; German non-Rx revenue recovered in August and September after a softer July.
• The adjusted EBITDA margin forecast remains 2.5%–3.0%; the margin was flat quarter-on-quarter, supported by operating leverage.
• Redcare will publish its Q3 2026 interim statement and hold a conference call on October 29, 2026.

The next important date, Berenberg Non-Deal Roadshow, Helsinki (NDR = “non-deal roadshow”), at Redcare Pharmacy is on 29.09.2026.

The price of Redcare Pharmacy at the time of the news was 65,50EUR and was up +8,49 % compared with the previous day.
15 minutes after the article was published, the price was 64,95EUR this corresponds to a minus of -0,84 % since publication.
At this time, the index SDAX was at 18.221,90PKT (+0,39 %).

Redcare Pharmacy

-1,07 %

+4,06 %

+27,62 %

+5,74 %

-17,08 %

-35,11 %

-46,48 %

+145,64 %

+139,75 %

ISIN:NL0012044747WKN:A2AR94

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max

Redcare Pharmacy direkt bei SMARTBROKER+ handelnKaufVerkauf

Prämie Jetzt bis zu 120 € Prämie sichern! Egal ob Trading, Sparen oder beides - bei SMARTBROKER+ ist für alle was dabei. Jetzt Depot eröffnen und sichern!

Schreibe Deinen Kommentar